The West African Network for Clinical Trials of Antimalarial Drugs (WANECAM), a consortium of ten academic organisations in Africa and Europe, starts off the ‘WANECAM 2’ study in Bamako, Mali with a meeting on 15 April 2019. EDCTP invests EUR 10 million in the project. WANECAM will conduct clinical trials of a novel antimalarial combination comprising KAF156 (ganaplacide) and lumefantrine in a new once-daily formulation. The project is led by Professor Abdoulaye Djimdé of the Université des Sciences, Techniques et Technologies de Bamako.
The consortium will collaborate with the not-for-profit product development partnership Medicines for Malaria Venture (MMV) and the pharmaceutical company Novartis to develop its compound KAF156 in combination with lumefantrine. The aim is to advance the development of a much-needed new antimalarial therapy while strengthening clinical trial development capabilities in Africa.